Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Observational Trial Assessing the Clinical Benefit of Molecular Profiling in Patients With Solid Tumors

Trial Profile

An Observational Trial Assessing the Clinical Benefit of Molecular Profiling in Patients With Solid Tumors

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 05 Jul 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pembrolizumab (Primary)
  • Indications Carcinoma; Glioma; Lymphoma; Multiple myeloma; Non-small cell lung cancer; Pancreatic cancer; Solid tumours
  • Focus Therapeutic Use
  • Acronyms The Strata Trial
  • Sponsors Strata Oncology
  • Most Recent Events

    • 06 Jun 2023 Results assessing immunotherapy response score for predicting pembrolizumab clinical benefit in patients with advanced solid tumors presented at the 59th Annual Meeting of the American Society of Clinical Oncology
    • 19 Apr 2023 Results (n=176) assessing an integrative Immunotherapy Response Score performance for predicting pembrolizumab mono benefit in a second, independent validation cohort, presented at the 114th Annual Meeting of the American Association for Cancer Research.
    • 23 Jul 2021 New trial record
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top